Literature DB >> 15886304

Epidemiology of lung cancer: looking to the future.

Anthony J Alberg1, Malcolm V Brock, Jonathan M Samet.   

Abstract

In the United States, the 20th century witnessed the emergence of a lung cancer epidemic that peaked and began to decline by the century's end, a decline that continues today. However, lung cancer continues to be an unabating pandemic. In research carried out over the last half of the 20th century, many factors were causally associated with lung cancer and studies were implemented to identify determinants of susceptibility to these factors. Cigarette smoking was identified as the single most predominant cause of the lung cancer epidemic, but other causes were found, including workplace agents (eg, asbestos, arsenic, chromium, nickel, and radon) and other environmental factors (passive smoking, indoor radon, and air pollution). Contemporary epidemiologic research on lung cancer now focuses on a new set of issues, primarily related to susceptibility to the well-identified causal factors, particularly smoking, and on the consequences of changes in tobacco products for risks to smokers. Diet and the possibility of reducing risk through chemoprevention remain a focus of research emphasis through experimental and observational approaches. Questions have also been raised about possible differences in susceptibility to lung cancer by sex and race. Population patterns in smoking prevalence will continue to be the most powerful predictor of the future occurrence of lung cancer. Evaluation of recent US patterns in smoking prevalence indicates that for the next approximately 10 to 15 years, lung cancer rates will decrease, but will then level off starting in approximately 2030. Unless further reductions in the prevalence of cigarette smoking are achieved over the next decade, lung cancer will remain as an all too common, but avoidable, disease.

Entities:  

Mesh:

Year:  2005        PMID: 15886304     DOI: 10.1200/JCO.2005.10.462

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  132 in total

Review 1.  Parity and risk of lung cancer in women: systematic review and meta-analysis of epidemiological studies.

Authors:  Issa J Dahabreh; Thomas A Trikalinos; Jessica K Paulus
Journal:  Lung Cancer       Date:  2011-12-09       Impact factor: 5.705

2.  Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis.

Authors:  Michael J Jarzynka; Ping Guo; Ifat Bar-Joseph; Bo Hu; Shi-Yuan Cheng
Journal:  Int J Oncol       Date:  2006-02       Impact factor: 5.650

3.  Decline in respiratory symptoms in service workers five months after a public smoking ban.

Authors:  T M L Eagan; J Hetland; L E Aarø
Journal:  Tob Control       Date:  2006-06       Impact factor: 7.552

Review 4.  How cigarette smoke skews immune responses to promote infection, lung disease and cancer.

Authors:  Martin R Stämpfli; Gary P Anderson
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

5.  The effect of different doses of cigarette smoke in a mouse lung tumor model.

Authors:  Ludmilla Nadir Santiago; Juliana de Camargo Fenley; Lúcia Campanario Braga; José Antônio Cordeiro; Patrícia M Cury
Journal:  Int J Clin Exp Pathol       Date:  2008-08-25

6.  Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Aurea Lima; Vítor Seabra; Sandra Martins; Ana Coelho; António Araújo; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

Review 7.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

8.  Pulmonary resection for non-small cell lung cancer in patients with hepatocellular carcinoma.

Authors:  Takashi Iwata; Noritoshi Nishiyama; Koshi Nagano; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Takuma Tsukioka; Shoji Hanada; Kiyotoshi Inoue; Shoji Kubo; Shigekazu Takemura; Shigefumi Suehiro
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

9.  Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis.

Authors:  Wen Li; Li-Qiang Song; Jian Tan
Journal:  Tumour Biol       Date:  2014-06-18

10.  Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study.

Authors:  Hekmat Osman Abdel-Aziz; Yoshihiro Murai; Ichiro Takasaki; Yoshiaki Tabuchi; Hua-chuan Zheng; Kazuhiro Nomoto; Hiroyuki Takahashi; Koichi Tsuneyama; Ichiro Kato; Daniel K Hsu; Fu-tong Liu; Koichi Hiraga; Yasuo Takano
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.